Immutep’s Efti Combination Therapy Shows Promising Results in Soft Tissue Sarcoma Trial

The latest announcement is out from Immutep ( (IMMP) ).

Immutep Limited announced on May 26, 2025, that its EFTISARC-NEO Phase II trial, which evaluates the combination of eftilagimod alfa (efti) with radiotherapy and KEYTRUDA® for resectable soft tissue sarcoma, has successfully met its primary endpoint. The trial demonstrated significant improvement in tumor hyalinization/fibrosis, surpassing historical data from radiotherapy alone, indicating potential enhanced survival outcomes for patients. This development highlights a promising advancement in the treatment of this aggressive cancer, addressing a high unmet medical need.

The most recent analyst rating on (IMMP) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Immutep stock, see the IMMP Stock Forecast page.

Spark’s Take on IMMP Stock

According to Spark, TipRanks’ AI Analyst, IMMP is a Neutral.

Immutep’s overall stock score is driven by its financial performance, which shows typical biotech development phase challenges with ongoing losses and cash burn, but a stable balance sheet. Technical analysis indicates some positive trend momentum, while valuation remains weak due to negative earnings. The company’s ability to sustain operations relies heavily on securing continued financing and achieving future product success.

To see Spark’s full report on IMMP stock, click here.

More about Immutep

Immutep is a late-stage biotechnology company focused on developing novel immunotherapies for cancer and autoimmune diseases. The company is a leader in the research and development of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), aiming to leverage its expertise to provide innovative treatment options and maximize shareholder value.

Average Trading Volume: 289,993

Technical Sentiment Signal: Hold

Current Market Cap: $267.6M

For a thorough assessment of IMMP stock, go to TipRanks’ Stock Analysis page.